• Onco-Innovations completed an analytical reference standard program for A83B4C63, the API supporting its lead oncology candidate ONC010.
• Work with Dalton Pharma produced highly characterized material for future testing of identity, purity, potency, stability, impurity profiles, batch comparability.
• Milestone sets an analytical benchmark for future manufacturing campaigns, supporting quality systems, regulatory documentation, clinical-readiness efforts for ONC010.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607101800ACCESSWRNAPR_____1189547) on July 10, 2026, and is solely responsible for the information contained therein.